A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Influenza virus vaccine (Primary) ; JNJ 64400141 (Primary)
- Indications Influenza virus infections; Respiratory syncytial virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Janssen Vaccines and Prevention B.V
- 22 Dec 2023 Results assessing immunogenicity and safety of concomitant administration of Ad26.RSV.preF/RSV preF protein and high-dose seasonal influenza vaccine (Fluzone-HD) in adults >-65 years old, published in the Journal of Infectious Diseases.
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 10 May 2022 Status changed from recruiting to active, no longer recruiting.